Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

Inclusion Criteria: \- For All Participants: 1. Provide written informed consent prior to the conduct of any study related procedures; 2. With a minimum body weight (BW) of 50 kg and within a Body Mass Index (BMI) range of 18.0 to 30.0 kg/m\^2 (all inclusive) at Screening visit; 3. Medically healthy as determined by the Investigator or medically qualified designee at both Screening and Inclusion visits. This will include no variation of BW of more than 5 percent between Screening and Inclusion visits; 4. Absence of clinically relevant abnormalities identified by a detailed medical history and complete physical examination; 5. Healthy participants, as determined by Normal Blood Pressure (BP) and Heart Rate (HR) at the screening and Inclusion visits after 5 minutes in supine position; 6. Normal ECG recording on a 12-lead ECG at the screening and Inclusion visits and no sign of any trouble of sinusal automatism, or considered as non clinically significant by investigator; 7. Laboratory parameters within the normal range of the laboratory; 8. Able to comprehend and willing to sign an Informed Consent Form, and to abide by the study restrictions; 9. Non-smoker participant or smoker of not more than 5 cigarettes/day within 3 months prior to Inclusion visit, and able to restrain from smoking during the whole study duration; 10. Participant with normal dietary habits; 11. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research; * For Healthy Young Volunteers only: 12. Males or females, between 18 and 45 years of age (all inclusive) at screening; 13. Matched to healthy elderly participants by BMI (plus or minus 20 percent) and gender; 14. Females participating in this study must be of non-childbearing potential or using highly efficient contraception for the full duration of the study and for 1 month after the end of treatment; 15. Females of childbearing potential must have a negative qualitative serum pregnancy test at Screening visit and a negative urine pregnancy test at Inclusion visit; * For Elderly volunteers only: 16. Males or females aged 75 years old or older at Screening visit; 17. Participants with mild, chronic, stable disease and stable treatment dose - no change in dose for the 3 months prior to Screening visit - (hypertension, hyperlipidemia, osteoarthritis, treated benign prostate hypertrophy, stable and treated hypothyroidism, treated glaucoma); 18. Participants with suitable veins for cannulation or repeated venipuncture. Exclusion Criteria: \- For all participants: 1. Participants with a history of noncompliance to medical regimens; 2. Participant who, in the opinion of the Investigator, is likely to be not respectful or not cooperative during the study, or unable to cooperate because of a language problem or a mental deficiency; 3. Participant who cannot be contacted in case of emergency; 4. Participant who is in the exclusion period of a previous study; 5. Administrative or legal supervision; 6. Inability to abstain from intensive muscular effort; 7. Participant who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study; 8. A positive alcohol test result or urine screen for drugs of abuse result at Screening or Inclusion visits; 9. Any history or suspicion of alcohol abuse; 10. Any history or suspicion of consumption of any drug of abuse (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, methamphetamines, methadone, methylenedioxymethamphetamine, opiates, tricyclic antidepressant), from screening to end of the study; 11. Consumption of nutritional supplements, herb-containing drug preparations (including Chinese medicines) or other foods or beverages (e.g., grapefruit and xanthine-containing foods or beverages) that may affect drug-metabolizing enzymes or transporters from screening to end of the study visit; 12. Evidence or history of gastrointestinal, hepatic, or renal disease, surgery or resection that would potentially alter absorption, distribution, metabolism, or excretion of orally administered drugs; 13. Participants who have clinically significant disease of cardiovascular, respiratory, renal, endocrine, hematological, gastrointestinal, neurological (central nervous system), psychiatric, systemic, infectious disorders or malignant tumor; 14. General anesthesia within 3 months before administration; 15. History or presence of allergy or unusual reactions to some drugs or anesthetics or known hypersensibility to the investigation product or its excipients; 16. Major surgery within 28 days prior to Screening visit or major surgery planned within 6 months following participation to the study; 17. Blood donation within 2 months before administration or blood donation planned during the study or within 2 months following participation to the study; 18. Receipt of blood products within 2 months prior to Inclusion visit; 19. Participants with symptomatic hypotension at Screening visit, whatever the decrease of blood pressure, or asymptomatic postural hypotension defined by a decrease in SBP ≥ 20 mmHg or DBP ≥ 10 mmHg within 3 minutes when changing from the supine to the standing position; 20. Frequent headaches and/or migraines, recurrent nausea and/or vomiting; 21. Participants who are positive for human immunodeficiency virus antibody, hepatitis B virus surface antigen, hepatitis C virus antibody; 22. Significant, uncontrolled, or life-threatening condition or organ or disease; 23. Show evidence of active renal disease (e.g. diabetic renal disease, polycystic kidney disease) or estimated glomerular filtration rate \<60 mL/min/1.73m²; 24. Evidence of pelvic organ prolapsed, incontinence, or fistula of the urogenital system; 25. Have a history of syncope, presyncope, uncontrolled vertigo, postural dizziness, or at risk for falls, as judged to be clinically significant by the investigator; 26. Any drug intake during the 2 weeks or 5 half-life of the drug preceding the first administration except those defined in concomitant medication section * For Young Adults Volunteers only: 27. Females who are pregnant or breastfeeding. Female participants should not be enrolled if they plan to become pregnant during the time of study participation; 28. Any medications (except paracetamol 3g/day or contraception) intake within the 2 weeks or 5 half-life prior to Screening visit; 29. Evidence or history of clinically significant metabolic or allergic disease.